GLP-1 Receptor Agonists for Diabetes: Evidence and Outcomes

Evidence on outcomes studied for GLP-1 Receptor Agonists

Evidence related to GLP-1 receptor agonist therapies in diabetes studies.

Studies

100

Evidence Pairs

Limited Evidence

Evidence Strength: 49/100

Evidence summary for AI and search

Among 40 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

Research documents analyzed

Evidence Pairs

100

Intervention-outcome relationships

Latest Publication

May 2026

Evidence Snapshot

Qualitative overview of the evidence landscape

Low Confidence

Based on 40 studies, emerging evidence suggests HbA1c, Body weight, Cardiovascular events are the strongest-supported outcomes for glp-1 receptor agonists.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Evidence freshness

May 2026

Latest indexed

Evidence Story

GLP-1 Receptor Agonists evidence appears to center on HbA1c.

Among 40 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: May 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 12 evidence pairs - 28 studies

Why this appears here

Moderate evidenceConsistent resultsPositive effect signalMultiple RCTs

HbA1c

22 studies

EvidenceScore™

70/100

ConsensusScore™

92/100

Body weight

20 studies

EvidenceScore™

67/100

ConsensusScore™

88/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c

Body weight

HbA1c

22 studies

EvidenceScore™

70/100

ConsensusScore™

92/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present

Evidence basis: 17 evidence pairs - 32 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Cardiovascular events may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Cardiovascular events

Total cholesterol

Cardiovascular events

3 studies

EvidenceScore™

61/100

ConsensusScore™

100/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength

Evidence basis: 6 evidence pairs - 11 studies

View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

What outcomes has GLP-1 Receptor Agonists been studied for?

outcomes studied

Emerging Evidence

HbA1c, Body weight, and Cardiovascular events are among the most studied areas in relation to GLP-1 Receptor Agonists.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.9 | strong positive | ConsensusScore™ Consistent | 22 studies
2
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 67.0 | strong positive | ConsensusScore™ Consistent | 20 studies
3
Cardiovascular events
EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 3 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 40 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

Does GLP-1 Receptor Agonists improve HbA1c?

intervention outcome_effect

Moderate Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.9 | strong positive | ConsensusScore™ Consistent | 22 studies

Why this answer: This answer is based on 22 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 22 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

Does GLP-1 Receptor Agonists affect body weight?

intervention outcome_effect

Emerging Evidence

GLP-1 Receptor Agonists may improve Body weight.

ConsensusScore™: Results are consistent across studies.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 67.0 | strong positive | ConsensusScore™ Consistent | 20 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Applicability

Population details were available for 1 of 20 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

Which outcomes have the strongest evidence for GLP-1 Receptor Agonists?

evidence strength

Emerging Evidence

HbA1c, Body weight, and Cardiovascular events have the strongest available evidence signals for GLP-1 Receptor Agonists.

ConsensusScore™: Results are consistent across studies.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.9 | strong positive | ConsensusScore™ Consistent | 22 studies
2
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 67.0 | strong positive | ConsensusScore™ Consistent | 20 studies
3
Cardiovascular events
EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 3 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Applicability

Population details were available for 1 of 28 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

Where does GLP-1 Receptor Agonists need more research?

research gaps

Emerging Evidence

BMI, Total cholesterol, and Triglycerides need more research in relation to GLP-1 Receptor Agonists.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 6 studies
2
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 1 study
3
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 54.8 | strong positive | ConsensusScore™ Consistent | 2 studies

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

How does GLP-1 Receptor Agonists compare across studied outcomes?

cross outcome_comparison

Emerging Evidence

HbA1c, Body weight, and Cardiovascular events have available evidence for GLP-1 Receptor Agonists, but the comparison requires review of the underlying studies.

ConsensusScore™: Results are consistent across studies.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.9 | strong positive | ConsensusScore™ Consistent | 22 studies
2
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 67.0 | strong positive | ConsensusScore™ Consistent | 20 studies
3
Cardiovascular events
EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 3 studies

ConsensusScore™

Consistent

Direction: strong positive

Across 2 studies, Liraglutide shows a consistent strong positive signal for HbA1c.

2 studies

EvidenceScore™: 60.65/100

View supporting studies

Studies evaluating GLP-1 Receptor Agonists

Studies connected to this intervention in the evidence record.

Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes

May 16, 2026

Highly relevant

Interventions:

Liraglutide Semaglutide Tirzepatide

Outcomes:

BMI Body weight HbA1c Total cholesterol

View research summary→

Switching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics

May 30, 2026

Recent

Interventions:

Dulaglutide Tirzepatide

Outcomes:

Adverse events incidence Body weight Gastrointestinal disorders incidence HbA1c

View research summary→

Tirzepatide shows greater HbA1c and weight reduction than Semaglutide

Representative

Interventions:

Semaglutide Tirzepatide

Outcomes:

Body weight HbA1c Weight change

View research summary→

SMS Program Improves Transition from Insulin to GLP-1 RA in Diabetes

Representative

Interventions:

GLP-1 receptor agonists

Outcomes:

Hyperglycemia events Percentage of SMS text message responses reporting hypoglycemia (<80 mg/dL)Percentage of patients discharged on maximum GLP-1 RA dose Percentage of patients with GLP-1 RA dose increased by at least one level Percentage of patients with insulin dose reduction by at least 50%Percentage of patients with insulin stopped completely

View research summary→

Oral semaglutide improves glycemic control in type 2 diabetes

Representative

Interventions:

Semaglutide

Outcomes:

Body weight HbA1c

View research summary→

Survodutide improves HbA1c and bodyweight in type 2 diabetes

Representative

Interventions:

Semaglutide

Outcomes:

Body weight

View research summary→

Click outcomes and interventions to filter the archive when links are available.

Explore all GLP-1 Receptor Agonists evidence

Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.

Explore all GLP-1 Receptor Agonists evidence

Filter by study type, publication date, effect size, and more to refine your research